Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

Blood (2016) 128 (22): 4208.

https://doi.org/10.1182/blood.V128.22.4208.4208

Published: 2016

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Bouthaina S. Dabaja, MD, Jack Phan, MD PhD, L. Jeffrey Medeiros, MD, F.B. Hagemeister, MD, Hubert Chuang, MD, Luis Fayad, MD, Ferial Shihadeh, MD, Pamela Allen, PhD, Christine Wogan, MS, Maria A. Rodriguez, MD

Blood (2011) 118 (21): 2695.

https://doi.org/10.1182/blood.V118.21.2695.2695

Published: 2011

Journal Articles

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Nathan H. Fowler, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Maria A. Rodriguez, MD, Barbara Pro, MD, F.B. Hagemeister, MD, Anas Younes, MD, Jatin J Shah, MD, Larry W Kwak, MD, PhD, Diana Rodriguez, Peter McLaughlin, MD

Blood (2011) 118 (21): 99.

https://doi.org/10.1182/blood.V118.21.99.99

Published: 2011

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Xiao Zhou, MD, Auris Huen, Pharm, Shyam Teegala, MD, Yuan Ji, MD, Luis Fayad, MD, F.B. Hagemeister, MD, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 3993.

https://doi.org/10.1182/blood.V110.11.3993.3993

Published: 2007

Journal Articles

Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin’s Lymphoma Patients.

Michael A. Thompson, MD, PhD, Auris Huen, PharmD, Gregory D. Ayers, MS, Bela B. Toth, DDS, Rena V. Sellin, MD, Ana O. Hoff, MD, William A. Murphy, Jr., MD, F.B. Hagemeister, MD

Blood (2006) 108 (11): 4607.

https://doi.org/10.1182/blood.V108.11.4607.4607

Published: 2006

Journal Articles

Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma.

Felipe Samaniego, MD, Luis E. Fayad, MD, Barbara Pro, MD, Peter McLaughlin, MD, Maria Alma Rodriguez, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Sattva Neelapu, MD, Anas Younes, MD, Larry W. Kwak, MD

Blood (2006) 108 (11): 4722.

https://doi.org/10.1182/blood.V108.11.4722.4722

Published: 2006

Journal Articles

Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3.

Luis Fayad, MD, Michael Overman, MD, Barbara Pro, MD, Peter McLaughlin, MD, Felipe Samaniego, MD, Anas Younes, MD, Jorge Enrique Romaguera, MD, F.B. Hagemeister, MD, Larry Kwak, MD, Maria Alma Rodriguez, MD

Blood (2006) 108 (11): 2770.

https://doi.org/10.1182/blood.V108.11.2770.2770

Published: 2006

Journal Articles

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

F.B. Hagemeister, MD, P. McLaughlin, MD, L. Fayad, MD, F. Samaniego, MD, N. Dang, MD, A. Goy, MD, J. Romaguera, MD, B. Pro, MD, V. Beasley, R.N., F. Cabanillas, MD, M. Rodriguez, MD

Blood (2005) 106 (11): 941.

https://doi.org/10.1182/blood.V106.11.941.941

Published: 2005

NARROW

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin’s Lymphoma Patients.

Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma.

Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3.

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only